BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 27157843)

  • 1. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
    Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma.
    Mishra D; Sinha BP; Kumar MS
    Korean J Ophthalmol; 2014 Oct; 28(5):399-407. PubMed ID: 25276082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination.
    Centofanti M; Oddone F; Gandolfi S; Hommer A; Boehm A; Tanga L; Sangermani C; Sportelli V; Haustein M; Manni G; Rossetti L
    Am J Ophthalmol; 2010 Oct; 150(4):575-80. PubMed ID: 20688314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.
    Stalmans I; Oddone F; Cordeiro MF; Hommer A; Montesano G; Ribeiro L; Sunaric-Mégevand G; Rossetti L
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1151-8. PubMed ID: 26907933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study.
    Centofanti M; Oddone F; Vetrugno M; Manni G; Fogagnolo P; Tanga L; Ferreri P; Rossetti L
    Eur J Ophthalmol; 2009; 19(1):66-71. PubMed ID: 19123151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
    Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
    Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol.
    Mesci C; Aydin N; Erbil HH
    J Glaucoma; 2011 Oct; 20(8):477-81. PubMed ID: 21048508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.